A Multicenter, Retrospective Study Comparing the Real-World Efficacy and Safety of Apremilast Monotherapy (MT) to Combination Therapy (CT) for the Treatment of Plaque Psoriasis (PP)

Trial Profile

A Multicenter, Retrospective Study Comparing the Real-World Efficacy and Safety of Apremilast Monotherapy (MT) to Combination Therapy (CT) for the Treatment of Plaque Psoriasis (PP)

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 May 2018

At a glance

  • Drugs Apremilast (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 May 2018 Results (n=48) evaluating long term, 52 week efficacy and safety published in the Journal of the American Academy of Dermatology
    • 16 Oct 2017 New trial record
    • 05 Oct 2017 Results published in the Journal of the American Academy of Dermatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top